Summarized by Masters of Longevity from PR Newswire.
Japan launched Leqembi Pen, a once-weekly subcutaneous treatment for early Alzheimer’s.
Key Takeaways
- Leqembi Pen is approved for 500 mg once-weekly dosing.
- Leqembi Pen was added to Japan's National Health Insurance list.
- At-home administration may reduce IV clinic visits and resources.
